Your SlideShare is downloading. ×
0
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Good Manufacturing Practices (GMP), Good Laboratory Practices ...
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Good Manufacturing Practices (GMP), Good Laboratory Practices ...

7,027

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
7,027
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
351
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • On May 25, 2005, the Food and Drug Administration (FDA) will issue its Current Good Tissue Practice (CGTP) for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), representing the last of three FDA rules* that have been developed to improve the safety of HCT/Ps by preventing the introduction, transmission, and spread of communicable disease. The CGTP regulations will require HCT/P establishments to recover, process, store, label, package, and distribute HCT/Ps in a way that prevents the introduction, transmission, or spread of communicable diseases. HCT/P establishments must also maintain complaint files and evaluate each complaint relating to core CGTP requirements. Such establishments will also be required to 1) investigate any adverse reaction involving a communicable disease related to an HCT/P they made available for distribution and 2) report to FDA any serious adverse reactions involving a communicable disease. Serious adverse reactions are defined by FDA as fatal, life-threatening, resulting in permanent impairment of a body function or permanent damage to body structure, or necessitating medical or surgical intervention, including hospitalization. The establishments will be required to use the FDA MedWatch mandatory reporting form (Form FDA-3500A) and submit each report to FDA within 15 days of initial receipt of the information. This will be the first federal requirement for reporting of adverse reactions from transplanted HCT/Ps. Nearly simultaneously with the CGTP rule, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) revised its standards for the Laboratory Accreditation Program (revised standards QC.5.300, QC.5.310, and QC.5.320) and adopted these standards for the Ambulatory Care, Office-Based Surgery, Critical Access Hospital, and Hospital Accreditation programs (new standards PC.17.10, PC.17.20, and PC.17.30) ( 1,2 ). Effective July 1, 2005, these standards will apply to accredited organizations that store or issue tissue. These new standards will require that organizations assign oversight responsibility for a tissue program, use standardized procedures in all tissue handling, maintain traceability of all tissues, and have a process for investigating and reporting adverse events. All adverse events involving tissues, including disease transmission or other complications suspected of being directly related to tissue use, are to be investigated and reported to the HCT/P establishment from which the tissue was received. Improved HCT/P adverse event surveillance from these two mandatory reporting rules is anticipated to improve the overall safety of HCT/Ps and reduce risk to HCT/P recipients. A successful surveillance system will be contingent upon reporting by physicians, infection-control practitioners, risk managers, and others who identify adverse events. Along with receiving mandatory reports from establishments, FDA continues to encourage direct voluntary reports through its MedWatch program by using MedWatch Form FDA-3500, available at http://www.fda.gov/medwatch . Additional information about FDA and HCT/Ps is available at http://www.fda.gov/cber/tiss.htm . References Joint Commission on Accreditation of Healthcare Organizations. Revised laboratory standards: QC.5.300, QC.5.310, and QC.5.320. Oakbrook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations; 2005. Available at http://www.jcrinc.com/subscribers/perspectives.asp?durki=9162&site=10&return=6066 . Joint Commission on Accreditation of Healthcare Organizations. Standards for tissue storage and issuance: PC.17.10, PC.17.20, and PC.17.30. Oakbrook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations; 2005. Available at http://www.jcrinc.com/subscribers/perspectives.asp?durki=9160&site=10&return=6065 . * Federal Register 66 FR 5447, January 19, 2001; 66 FR 29786, May 25, 2004; and 69 FR 68612, November 24, 2004.
  • What is the Center for Biologics Evaluation and Research (CBER)? CBER is the Center within FDA that regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. CBER protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. CBER also provides the public with information to promote the safe and appropriate use of biological products. The Center for Drug Evaluation and Research ( CDER ), which assures that safe and effective drugs are available to the American people, has gone through a functional and organizational metamorphosis since it began as a one-man operation to assess significant drug problems in the marketplace on the eve of the 1906 Pure Food and Drugs Act
  • Tremendous pressure to obtain and distribute a vaccine.
  • Previously, vaccine associated polio had been indicated in earlier vaccine studies (20 years earlier) when paralysis was initiated in the vaccination arm.
  • Concerns about residual live virus had been raised. Concerns raised about consistency of manufacturing and inactivation.
  • Transcript

    • 1. Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP) and Good Tissue Practices (GTP) Richard E. Giles, Ph.D. Associate Professor Regulatory Affairs Institutional Compliance Office
    • 2. The Questions
      • What?
        • GLPs, GMPs & GTPs
        • General Definitions
        • Scope & Details
      • Who?
        • Users
        • Oversight
      • Why?
        • Need Based Origin
        • Ethical Requirements
        • Statutory Requirements
        • Institutional Impacts
      • Where?
        • Applicability in Processes
        • Institution/Sponsors/ & Outside Providers
      • When?
        • Project/Program Stage
        • Key Milestones
      • How?
        • Tasks
        • Personnel
        • Resources
    • 3. What Are They? Regulatory Requirements for the Manufacture and Testing of Drugs, Biological Products, Human Cells & Human Tissues and Devices.
    • 4. What are GLPs?
      • GLPs describe good laboratory practices for conducting non-clinical laboratory studies that support or are intended to support applications for research or marketing permits for products regulated by the FDA. 21 CFR Part 58.
      • Compliance with GLPs is intended to assure the quality and integrity of the safety data filed pursuant to the Food, Drug and Cosmetic Act and sections of the Public Health Service Act.
      • Applicable to drugs, biologicals, devices, INDs (Investigational New Drug application) & IDEs (Investigational Device Exemption).
      • Compliance with GLPs not required for research outside the regulatory scope of the FDA.
      • Requirements for CLIA ( Clinical Laboratory Improvement Act ) Compliance, CAP ( College of America Pathologist ) Compliance and FACT ( Foundation for the Accreditation of Cellular Therapies ) Accreditation are similar in many aspects to GLPs.
    • 5. What Are GMPs?
      • Good Manufacturing Practices are defined in 21 CFR for Drugs and Pharmaceuticals in parts 210 & 211 and for Biologicals in parts 600-680.
        • Overlapping requirements occur.
      • GMPs pertain to the minimum current good manufacturing practice for preparation of drug products for administration to humans or animals or for preparation of biological products for administration to humans.
      • There are overlaps between GMPs, GTPs and FACT requirements.
    • 6. What are GTPs?
      • The FDA has defined Good Tissue Practices for Human Cells, Tissues, and Cellular and Tissue-Based Products for the Prevention of the Introduction, Transmission, or Spread of Communicable Diseases.
      • Definition: HCT/P = ‘‘human cells, tissues, or cellular or tissue-based products.’’
      • 1270—Human Tissue Intended for Transplantation.
      • 1271—Human Cells, Tissues, & Cellular and Tissue-Based Products.
    • 7. A Process View of GLPs, GMPs & GTPs
    • 8.  
    • 9.  
    • 10. Applicability of GLPs, GMPs, and GTPs in Health Care & Clinical Research Institutions
      • Blood, Bone Marrow & Tissue Collection and Processing for Use in Human Recipients.
        • + FACT, CAP & CLIA
      • Clinical Trials
        • In-House Manufacturing.
        • Contract Manufacturing.
      • Pharmaceutical Operations
      • Laboratory Medicine & Medical Diagnostics (CAP & CLIA)
        • Standard Diagnostic Tests
        • Standard Infectious Agents Tests
        • Custom Testing Services
      • Production of Imaging Agents
    • 11. Who is Responsible for GLPs, GMPs & GTPs?
      • Institutional components performing tasks covered by GLPs, GMPs & GTPs
      • Institutional components performing oversight tasks
        • Compliance Office
        • Office or Regulatory Affairs
        • IRBs
        • Office of Research Administration
    • 12. Origin of GLPs, GMPs & GTPs
    • 13. FDA's Mission Statement
      • #1 The FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation.
      • #2 The FDA is also responsible for advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get the accurate, science-based information they need to use medicines and foods to improve their health.
    • 14. FDA Critical Path for Medical Product Development FDA: Challenge and Opportunity on the Critical Path to New Medical Products, March 2004 Modified
    • 15. Preclinical Versus Clinical Production
      • Objectives
        • address basic questions about function
        • test hypotheses & therapeutic approaches
      • Sources & Quality of Materials
        • may use uncharacterized outside materials
        • partial or minimal characterization
      • Minimal Use of Characterized Lab Reference Banks
      • Scale & Systems: small to medium
      • Limited repertoire of QC tests
      • Facilities & Equipment capable of GLP work. Performance & Validation inconsistent
      • Personnel training & experience in GLP variable; GMP very limited
      • Objectives.
        • produce FDA qualified materials for phase I-III trials.
      • Sources & Quality of Materials.
        • outside materials completely characterized & qualified prior to use in production.
      • Establishment & Maintenance of Well Characterized Reference Banks.
      • Scale & Systems: small through large.
      • Extensive in house repertoire of QC tests QA oversight.
      • Facilities & Equipment Validated for GMP work.
      • Personnel trained in GLP & GMP.
    • 16. Centers in the FDA
      • Center for Biologics Evaluation and Research
      • Center for Drug Evaluation and Research
      • Office of Regulatory Affairs
      • Center for Devices and Radiological Health
      • Center for Food Safety and Applied Nutrition
      • Center for Veterinary Medicine
      • National Center for Toxicological Research
      Modified from Zoon FDA jhu 99
    • 17. Combination Products
      • Combination products are assigned to a Center for review and regulation in accordance with the products' primary mode of action .
      • When a product's primary mode of action is attributable to a type of biological product assigned to CDER, the product will be assigned to CDER.
      • Similarly, when a product's primary mode of action is attributable to a type of biological product assigned to CBER, the product will be assigned to CBER.
    • 18. Useful Terms
      • Adventitious Microbial Agents : Agents such as bacteria, fungi, mycoplasma, or viruses not an integral part of a material that may be present as chance contaminants; extrinsic.
      • Gene Transfer Vector (used herein as “vector”): A vehicle composed of DNA (or RNA) for transferring a gene or other nucleic acid sequence of interest; frequently based on viruses, bacteriophage or bacterial plasmids. May be replication defective or competent.
      • Gene Therapy : Transfer of a gene or other nucleic acid sequence by means of a “vector” into a patient to obtain a therapeutic effect.
      • Transduce/Transduction : Transfer of a gene or nucleic acid sequence into a target cell or organism.
      • Monoclonal Antibody : An antibody preparation of uniform composition and specificity produced from a single cell origin “clone” of an antibody producing cell.
    • 19. Historical Background
    • 20. Polio Disease Incidence ~ 0.03%, 1953 National Foundation Field Trial: Largest and Most Comprehensive Test of a Medical Product "The Cutter Incident", Paul A. Offit, M.D., Yale Univ. Press, 2005
    • 21. Polio Epidemics "The Cutter Incident", Paul A. Offit, M.D., Yale Univ. Press, 2005
    • 22. National Foundation Field Trial Salk Vaccine
      • 420,000 children; Salk vaccine (Parke-Davis & Eli Lilly). 200,000 placebo. 1.2 million, nothing. Total 1.8 million.
      • 20,000 physicians & health officers; 40,000 registered nurses; plus 264,000 volunteer principals, teachers & citizens. Cost $7.5 M; today $ 5 B?
      "The Cutter Incident", Paul A. Offit, M.D., Yale Univ. Press, 2005
    • 23. Polio Vaccinations "The Cutter Incident", Paul A. Offit, M.D., Yale Univ. Press, 2005
    • 24. National Foundation Field Trial Result: Salk Vaccine
      • 16 children died of polio, none of whom received Salk vaccine.
      • 36 children developed severe polio (iron lung required) only two of whom received Salk vaccine.
      • Children who did not receive Salk vaccine were 3.3 times as likely to be paralyzed as vaccine recipients.
      • No polio cases were specifically associated with Salk vaccine.
      "The Cutter Incident", Paul A. Offit, M.D., Yale Univ. Press, 2005
    • 25. National Foundation Field Trial Licensing & Distribution: Salk Vaccine
      • Results announced the morning of April 12, 1954 Ann Arbor, Michigan.
      • HEW Secretary Hobby signed licenses April 12, 1954, 5:15 pm for Parke-Davis; Eli Lilly; and three additional companies that had submitted prior samples of vaccine (Pitman-Moore, Wyeth & Cutter).
      • Vaccines shipped shortly thereafter from 13 lots approved by the Laboratory of Biologics Control. Overall, forty lots of approximately 5 M doses distributed.
      "The Cutter Incident", Paul A. Offit, M.D., Yale Univ. Press, 2005
    • 26. Polio Among Recipients of Licensed Vaccine Lots
      • April 25, 1954, reports of polio among vaccine recipients begin. 6 cases of paralysis reported by 4/26 received vaccine from the same manufacturer, Cutter.
      • Cutter recalls vaccine 4/27.
      • Langmuir study follow-up.
        • 57 Children paralyzed; 5 died.
        • Vaccine induced disease more likely to be severe.
      • Infection of family & other contacts.
      • Estimates based on Shaw study in Idaho (per Offit) of Cutter lots with residual live virus
        • 200,000 infected.
        • 70,000 develop muscle weakness.
        • 164 severe paralysis.
        • 10 deaths.
      • Note: Wyeth also made vaccine that caused paralysis (lower frequency of contaminated lots)
      "The Cutter Incident", Paul A. Offit, M.D., Yale Univ. Press, 2005
    • 27. Problem Areas
      • Mahoney Strain of Type 1 Polio (Highly pathogenic)
        • Good representative of a “hot” virus strain for a protective immune response.
        • Bad if inactivation is incomplete.
      • Filtration
        • Seitz vs. Porous Glass.
        • Change in Quality of Porous Glass Filters. Due to change in staff (one key retirement).
      • Safety Tests
        • Cell Culture. Sample volume (0.1% of final vaccine).
        • Monkey. Subsequent studies revealed that cortisone treated monkeys demonstrated live virus in Cutter samples previously tested in monkeys without steroid. Inoculation into the spinal cord found to be 500 fold more sensitive for detecting live virus.
      • Bulk Intermediate Storage
        • Salk’s lab treated with formaldehyde within days of filtration.
        • Cutter often stored for weeks or sometimes months before inactivation.
        • Viral particle clumping over time.
      • Inactivation Kinetics
        • Salk recommended at least four sampling time points, with the last negative for virus. Total time of formaldehyde exposure = 3 x the time to reach the no detectable virus level.
        • Eli Lilly & Parke-Davis, six time points.
        • Cutter never determined when live virus FIRST eliminated. Disregard of Salk’s inactivation theory.
      • Inactivation Difficulties
        • Cutter never acknowledge difficulties in obtaining consistent inactivation (9 of 27 lots failed).
        • National Foundation selected Eli Lilly & Parke-Davis because they were the only companies to make at least 11 consecutive lots passing safety tests.
      "The Cutter Incident", Paul A. Offit, M.D., Yale Univ. Press, 2005
    • 28. Inactivation Kinetics Four Point Linearity In the Observable Region + Linear Extrapolation. Four Point Linearity In the Observable Region Requirement Not Followed by Cutter "The Cutter Incident", Paul A. Offit, M.D., Yale Univ. Press, 2005
    • 29. Adventitious Agents
      • SV40 in Polio
        • An “adventitious viral agent”. Was present in monkey kidney cells used to grow polio virus.
        • Found in both Salk & Sabin Vaccines, 1955-1963.
        • SV40 is more resistant to formaldehyde inactivation.
        • IOM Report 10/22/02.
          • Studies of groups of people who received polio vaccine during 1955-1963 provide evidence of no increased cancer risk.
          • However, because these epidemiologic studies are sufficiently flawed, the committee concluded in this report that the evidence was inadequate to conclude whether or not the contaminated polio vaccine caused cancer. In light of the biological evidence supporting the theory that SV40-contamination of polio vaccines could contribute to human cancers, the committee recommends continued public health attention in the form of policy analysis, communication, and targeted biological research.
        • CDC
          • Over 98 million Americans received one or more doses of polio vaccine during the period (1955-1963) when some of the vaccine was contaminated with SV40. SV40 has been found in certain types of human cancers, but it has not been determined that SV40 causes these cancers. The majority of evidence suggests there is no causal relationship between receipt of SV40-contaminated vaccine and cancer; however, some research results are conflicting and more studies are needed.
      • Qualification of MCBs & MSVs are Important!
    • 30. GLPs & GMPs Basic Components
    • 31. FDA Documents
      • Code of Federal Regulations.
        • Compliance Required.
        • Revisions & New Regulations Published in the Federal Register in draft version for comments before a Final Rule is Issued.
      • Guidance Documents .
        • Published initially on CBER & CDER web page for comments.
        • “… draft guidance, when finalized, will represent the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the appropriate FDA staff.”
        • Do not establish legally enforceable responsibilities.
        • Viewed as recommendation unless regulatory or statutory requirement cited.
      • Points to Consider.
        • Replaced by Guidance Documents.
        • Still relevant for understanding FDA/CBER positions.
    • 32. FDA Regulations: INDs & Clinical Trials
      • 21 Code of Federal Regulations (CFR) Part 58
        • Good Laboratory Practices (GLP)
      • 21 Code of Federal Regulations (CFR) Part 210-211
        • Good Manufacturing Practice (GMP)
      • 21 Code of Federal Regulations (CFR) Part 1270-1271
        • Good Tissue Practices (GTP)
      • 21 Code of Federal Regulations (CFR) Parts 50, 56 & 312
        • Good Clinical Practices (GCP)
        • Protection of Human Subjects, Part 50
        • Informed Consent Requirements, Part 50
        • IRB functions & responsibilities, Part 56
        • Investigational New Drug Application (IND), Part 312. General Provisions; Application Content & Format; Administrative Actions; Responsibilities of Sponsors & Investigators
    • 33. Other Relevant Regulations for Title 21, Code of Federal Regulations (CFR)
      • Parts 600 - 680 – Biologics
      • Part 820 - Quality System Regulation
      • Part 25 - Environmental Assessments
      • Part 201, 202 - Labeling & Advertising
      • Part 800 - In Vitro Diagnostics
      Modified from Zoon FDA jhu 99
    • 34. What Is Covered in GLPs & GMPs?
      • GLPs
        • Organization & Personnel
        • Facilities
        • Equipment
        • Testing Facilities Operation
        • Test and Control Articles
        • Protocol for and Conduct of a Nonclinical Laboratory Study
        • Records and Reports
      • GMPs
        • Organization & Personnel
        • Buildings & Facilities
        • Equipment
        • Control of Components, Containers & Closures
        • Production & Process Control
        • Holding & Distribution
        • Laboratory Controls
        • Records & Reports
        • Returned & Salvaged Products
    • 35. What Is Covered in GLPs?
      • Organization and Personnel
        • Personnel.
        • Testing facility management.
        • Study director.
        • Quality assurance unit.
      • Facilities
        • General.
        • Animal care facilities.
        • Animal supply facilities.
        • Facilities for handling test and control
        • articles.
        • Laboratory operation areas.
        • Specimen and data storage facilities.
      • Equipment
        • Equipment design.
        • Maintenance and calibration of equipment.
      • Testing Facilities Operation
        • Standard operating procedures.
        • Reagents and solutions.
        • Animal care.
      • Test and Control Articles
        • Test and control article characterization.
        • Test and control article handling.
        • Mixture of articles with carriers.
      • Protocol for and Conduct of a
      • Nonclinical Laboratory Study
        • Protocol.
        • Conduct of a Nonclinical laboratory
        • study.
      • Records and Reports
        • Reporting of nonclinical laboratory
        • study results.
        • Storage and retrieval of records and
        • data.
    • 36. What Is Covered in GMPs?
      • Organization & Personnel
        • QC Unit Responsibilities
        • Personnel Qualifications
        • Personnel Responsibilities
      • Buildings & Facilities
        • Design & Construction
        • Lighting
        • Ventilation, Air Filtration, Heating & Cooling
        • Plumbing
      • Equipment
        • Design, Size, Location, Construction, Cleaning, Maintenance
        • Validation
      • Control of Components, Containers & Closures
        • Receipt & Storage Untested Materials
        • Testing & Approval/Rejection
        • Use of Approved Materials
      • Production & Process Control
        • Written Procedures, Deviations
        • Yield Calculation
        • Equipment Identification
        • Sampling & Testing of In-process Materials
        • Sterility
        • Reprocessing
    • 37. What Else Is Covered by GMPs?
      • Packaging & Labeling
        • Materials & Usage
        • Issuance
        • Operations
        • Expiration Dating
      • Holding & Distribution
      • Laboratory Controls
        • Protocols & SOPs Drafted by the Appropriate Unit & Approved by QC Unit
        • Documentation at the Time of Performance
        • Any Deviations Documented and Justified
        • Conformance to Written Specifications for Acceptability
      • Laboratory Controls
        • Description of Sampling Procedure
        • In-Process Testing
        • Instrument & Apparatus Calibration & Validation
        • Testing & Release
        • Stability Testing
        • Special Testing
        • Reserve Samples
        • Animals
        • Penicillin Contamination
      • Records & Reports
      • Returned & Salvaged Products
    • 38. Quality Assurance (QA)
      • Quality Assurance
        • Process of monitoring a study to assure management that the facilities, equipment, personnel, methods, practices, records and controls are in accordance with applicable regulations
      • QA units typically report directly to senior management and not through Production Units or QC Units
      • QA units for Clinical Trials report directly to senior management
    • 39. GLP QA
      • Master Schedule Sheet (test article; test system; nature of study; date initiated; current status; sponsor; study director)
      • Maintenance of Protocols
      • Lab Inspections
      • Study Status Reports
      • Deviations from Protocols or SOPs
      • Review & Sign Final Study Report
    • 40. Quality Control (QC) I
      • Quality Control is the process, procedures and authority used to accept or reject all components, drug product containers, closures, in-process materials, packaging material, labeling and drug products and the authority to review production records to assure that no errors have occurred, or if errors have occurred, that they have been fully investigated.
    • 41. Quality Control II
      • QC unit has responsibility for approving or rejecting all procedures or specifications impacting on the identity, strength, quality and purity of the drug product
      • QC testing of ingredients, MCBs, MSV, Production Cells, Production Virus, In-Process Materials and Final Container Samples
    • 42. Quality Control III
      • QC unit tests are used for Lot Release documentation and preparation of Certificates of Analysis (CoAs).
      • QC units typically report directly to senior management and not through the Production Unit.
    • 43.  
    • 44. Criteria for Biologics & Drugs
      • Safety
      • Identity
      • Potency/Strength
      • Purity/Quality Efficacy
    • 45. Production Process
    • 46. Production Stages
      • Lab Stocks of Vectors and Producer Cells
      • Reference stocks of vectors and cells
      • Screen reference stocks for identity and adventitious agents
      • Produce Master Cell Bank (MCB)
      • Characterize & Qualify MCB
      • Produce Master Virus Bank (MVB)
      • Characterize & Qualify MVB
      • Produce Working Cell Bank (WCB)
      • Characterize & Qualify WCB
      • Produce Working Virus Bank (WVB)
      • Characterize & Qualify WVB Produce Production Cells
      • Produce Seed Virus
      • Produce a Production Serial
      • Produce Bulk Harvest
      • Qualify Bulk Harvest
      • Processing/Purification of Bulk Harvest
      • Fill Product in Final Containers
      • QC Testing of Bulk & Final Container Samples
      • Completion of QA
      • Completion of Lot Release Documents & Review
      • Lot Release
    • 47. Project Management for GMP Gene Therapy Vector Production Replication Defective Adenovirus Vector AdRB94
    • 48. Project Flow Chart
    • 49. AdRB94 Task List & Gantt Chart: Critical Tasks
    • 50. Investigational New Drug (IND) Applications (21 CFR 312)
      • 1 Form 1571
      • 2 Table of Contents
      • 3 Introductory Statement & General Investigational Plan
      • 4 Reserved
      • 5 Investigator’s Brochure
      • 6 Protocol
      • 7 Chemistry, Manufacturing & Control Information
      • 8 Pharmacology & Toxicology
      • 9 Previous Human Experience with the Investigational Drug
      • 10 Additional Information
      • Appendices
    • 51. Interaction With Commercial Sponsors Types of Interactions
      • Commercial Sponsor holds the IND
        • Commercial Sponsor and Performing Institution(s) develop a sponsored research agreement
        • Typically the commercial sponsor provides the required support; commercial sponsor provides partial support, e.g. drugs and/or materials
      • Institutional IND
        • Commercial Sponsor
        • Government Grant
        • Foundation Support
        • Institutional Support
        • Mixed Sources
    • 52. Contract Manufacturing & Testing
      • Evaluate the Contractors Capabilities.
        • Compliance with GLPs and GMPs.
        • Documentation.
        • Testing SOPs & Procedures.
        • Scheduling Capabilities.
        • Updates on tests in progress and tests scheduled.
        • FDA track records and records of FDA actions concerning the contractor. FDA Form 483s.
    • 53. GMPs for Phase I and Exploratory INDs
      • Challenge & Opportunity on the Critical Path to New Medical Products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
      • GMP for Phase I.
      • Exploratory INDs.
      • “ Science is rapidly coming to understandings of the genetic and molecular mechanisms of not just a disease like cancer, but diabetes, cardiovascular disease, and on and on. As that rapid scientific discovery is occurring, the FDA is committed to facilitating the rapid translation and the development of that knowledge into the development of new drugs or treatments that are going to alleviate those diseases. But rapid does not mean reckless. There is no compromise in the rigor of the clinical trials process, no compromise in the rigor of laboratory testing and animal testing, or on the standards that will be applied.” Remarks by Andrew C. von Eschenbach, M.D., Acting Commissioner of Food and Drugs, Thursday, January 12, 2006
    • 54. Topics
      • What
        • GLPs, GMPs & GTPs
        • General Definitions
        • Scope & Details
      • Who
        • Users
        • Oversight
      • Why
        • Need Based Origin
        • Ethical Requirements
        • Statutory Requirements
        • Institutional Impacts
      • Where
        • Applicability in Processes
        • Institution/Sponsors/ & Outside Providers
      • When
        • Project/Program Stage
        • Key Milestones
      • How
        • Tasks
        • Personnel
        • Resources
    • 55. Where Do I Go From Here?
      • Define Your Needs
      • Consult the References Section & Relevant Web Pages
      • Review Your Institutional Supporting Offices
      • Consult with Professional Colleagues
    • 56. Internet References
      • Code of Federal Regulations, http://www.gpoaccess.gov/cfr/index.html
      •   Federal Register, http://www.gpoaccess.gov/fr/index.html
      •   FDA, http://www.fda.gov/
      •   CBER, http://www.fda.gov/cber/index.html ;ntations, http://www.fda.gov/cber/summaries.htm
      • CBER Guidelines, http://www.fda.gov/cber/guidelines.htm
      • FDA Guidance for HGT http://www.fda.gov/cber/gdlns/somgene.pdf
      • Warning Letters, http://www.fda.gov/cber/efoi/warning.htm
      •   International Conference on Harmonization (ICH), http://www.ich.org/cache/compo/276-254-1.html
      • FDA: Challenge & Opportunity on the Critical Path to New Medical Products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
      • US Office of Public Health and Science, http://phs.os.dhhs.gov/ophs/ Gene Therapy  Links, http://www3.mdanderson.org:80/depts/genetherapy/links.html
      • National Gene Vector Laboratories, http://www.ngvl.org/facilities.php?facility=iu
      • Biosafety in Microbiological & Biomedical Laboratories, http://www.cdc.gov/od/ohs/biosfty/biosfty.htm
      • CDC, http://www.cdc.gov/
      • Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT), http://www.unmc.edu/Community/fahct/Home_Page.htm
      • American Association of Blood Banks, http://www.aabb.org/
      • NIH, http://www.nih.gov/
      • Office of Biotechnology Activities (OBA; formerly NIH-RAC),
      • http://www4.od.nih.gov/oba
      • NIH Guidelines, http://www4.od.nih.gov/oba/rac/guidelines/guidelines.html  US Dept of Health & Human Services http://www.os.dhhs.gov/
      • Office for Human Research Protections (OHRP), http://ohrp.osophs.dhhs.gov/
    • 57. Discussion Topics
      • GMPs for Phase I Clinical Trials
      • How much GLP & GMP do I need at my institution?
      • What can I do in-house & what to I contract?
    • 58. Interaction with Commercial Contractors or Sponsors
      • Scientific, Clinical & Commercial Objectives
      • Project Planning & Management
      • Protocol Development
      • Budget Development
      • Sponsored Research Agreement
      • Regulatory Documents & Approvals
      • Development of Written Implementing Protocols, SOPs, Testing Procedures and Assay Procedures
      • Validation of All Protocols, Tests & Assays and Reference Standards for Tests & Assays

    ×